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Abstract
Background: Analysis of gene expression and gene mutation may add information to be different from ordinary 
pathological tissue diagnosis. Since samples obtained endoscopically are very small, it is desired that more sensitive 
technology is developed for gene analysis. We investigated whether gene expression and gene mutation analysis by 
newly developed ultra-sensitive three-dimensional (3D) microarray is possible using small amount samples from 
endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) specimens and pancreatic juices.
Methods: Small amount samples from 17 EUS-FNA specimens and 16 pancreatic juices were obtained. After nucleic 
acid extraction, the samples were amplified with labeling and analyzed by the 3D microarray.
Results: The analyzable rate with the microarray was 46% (6/13) in EUS-FNA specimens of RNAlater® storage, and RNA 
degradations were observed in all the samples of frozen storage. In pancreatic juices, the analyzable rate was 67% (4/6) 
in frozen storage samples and 20% (2/10) in RNAlater® storage. EUS-FNA specimens were classified into cancer and 
non-cancer by gene expression analysis and K-ras codon 12 mutations were also detected using the 3D microarray.
Conclusions: Gene analysis from small amount samples obtained endoscopically was possible by newly developed 
3D microarray technology. High quality RNA from EUS-FNA samples were obtained and remained in good condition 
only using RNA stabilizer. In contrast, high quality RNA from pancreatic juice samples were obtained only in frozen 
storage without RNA stabilizer.
Background
The microarray is the advanced technology that is useful
for comprehensive gene expression profiling. Microarray
analysis has the possibility of identifying subsets of genes
that may be especially useful markers for cancer diagnosis
[1,2]. The Olympus Co.Ltd. (Tokyo, Japan) has developed
a novel microarray technology, the three dimensional
( 3 D )  m i c r o a r r a y  s y s t e m  i n  c o o p e r a t i o n  w i t h  P a m G e n e
International, B.V. (BJ's-Hertogenbosch, The Nether-
lands). This technology involves the use of a multi-porous
3D substrate and flow-through hybridization technique
with pumping sample solution rapidly and semi-automat-
ically (Figure 1). Unlike conventional microarrays that use
a 2D substrate such as a slide glass, the 3D microarray
binds a huge amount of probe DNA molecules onto a
solid 3D structure substrate (Figure 2) as previously
described [3,4].
Recently, detailed, global, genomic analyses have lead to
a better understanding of the pathogenesis of pancreatic
tumors. This has opened up avenues for the development
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of novel diagnostic and individually tailored treatment
strategies [5-9]. Microarrays have traditionally been
applied to pancreatic tissue obtained from surgical resec-
tion, but in this report, we investigated whether gene
analysis by 3D microarray is possible using small samples
obtained endoscopically for the pancreatic lesions.
Methods
Samples
This study was approved by the Institutional Review
Board of Nagoya University Graduate School of Medi-
cine. Written informed consents were obtained from all
patients. Seventeen endoscopic ultrasound-guided fine-
needle aspiration (EUS-FNA) specimens, pancreatic ade-
nocarcinoma (n = 11), chronic pancreatitis (n = 3), auto-
immune pancreatitis (n = 2) and pancreatic endocrine
tumor (n = 1), and 16 pancreatic juices, pancreatic adeno-
carcinoma (n = 1), chronic pancreatitis (n = 10) and intra-
ductal papillary mucinous neoplasms (n = 5) were
obtained in Nagoya University hospital. EUS-FNA was
carried out and the obtained samples were immediately
frozen in liquid nitrogen and stored at -80°C or immersed
in RNAlater® (Ambion Inc., Austin TX, USA) at 4°C for 16
hours and then stored at -20°C. Pancreatic juices samples
were obtained by endoscopic retrograde cholangiopan-
creatography (ERCP) and immediately frozen in liquid
nitrogen and stored at -80°C or mixed with 10 volume of
RNAlater® at 4°C for 16 hours and then stored at -20°C.
The endoscope and needles used for EUS-FNA was GF-
UCT 240 and NA-200H-8022 (22 gauge) (Olympus Co.
Ltd. Tokyo Japan). The endoscope and catheters used for
ERCP was JF-260V and PR-109-Q-1 (Olympus Co. Ltd.
Tokyo Japan).
Total RNA/DNA extraction
Both total RNA and genomic DNA were simultaneously
extracted from the same sample by ISOGEN (NIPPON
GENE Inc., Tokyo, Japan). EUS-FNA specimens were
pounded in a mortar with liquid nitrogen before extrac-
tion of the nucleic acids. Pancreatic juices stored by freez-
ing at -80°C were diluted with 10 volumes of PBS and
centrifuged by 2000 rpm for 10 minutes. The obtained
pellets were used for nucleic acid extraction. Pancreatic
juices stored by RNAlater® were centrifuged by 2000 rpm
f o r  1 0  m i n u t e s .  T h e  o b t a i n e d  p e l l e t s  w e r e  u s e d  f o r
nucleic acid extraction. The concentration of the
obtained nucleic acids was estimated by measuring the
optical density (OD) at 260 nm using a Nanodrop (Nano-
drop Inc., Wilmington, DE, USA) and their quality was
checked by electrophoresis using a Bioanalyzer (Agilent
Inc., Santa Clara, CA, USA).
Gene expression analysis
The 0.1-2 μg of total RNA derived from each sample was
amplified as aRNA by Eberwine's method using a Mes-
sage Amp™ aRNA kit (Ambion Inc.) and labeled with bio-
tin-16-UTP (Roche Inc.) [10].
Hybridization and image analysis were performed using
a 3D microarray (PamChip) and FD10 microarray system
developed by the Olympus Corporation. The microarray
was set up with 60 mer oligo DNA probes of 60 genes:
human gene related cancer, pancreatic enzyme, β-actin
(ACTB) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as house keeping genes and lambda DNA
(LAMD) and renilla luciferase gene (pRL-TK) as negative
controls. Each probe sequence was designed by Novus-
gene Inc. Hybridization, washing and fluorescence detec-
tion were performed semi-automatically in the FD10. The
50 ng of each labeled aRNA was dissolved in 3XSSPE,
including 0.5% Lauryl sarcosine and applied on Pamchip
and hybridization was performed at 42°C for 1.5 hours.
After the hybridization reaction, the Pamchip was
washed and fluorescent signals were amplified using an
enzymatic reaction kit (TSA™ Kit #22, Invitogen Inc.,
Figure 1 Schematic description of newly developed 3D microar-
ray technology. (a) The 3D microarray (PamChip) with the four array 
format (left), an array with a diameter of 45 mm (middle), and a set of 
oligo DNA probes immobilized with 120 μm diameter (right). (b) The 
partial top (left) and cross section view (right) of multi-porous substrate 
within PamChip. (c) FD10 microarray system with functions of hybrid-
ization, washing, fluorescence imaging and image analysis, which are 
integrated and performed semi-automatically.
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Figure 2 Comparison between 3D microarray (left) and conven-
tional 2D microarray (right).
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Carlsbad, CA, USA). The CCD images were automati-
cally taken by the FD10 and each image was analyzed by
the original analysis software. Hierarchical clustering by
UPGMA methods and the Welch t  statistic were per-
formed using Spotfire Decision Site Functional Genomics
ver.8.0 (Spotfire Inc., PaloAlto, CA, USA).
Gene mutation analysis (K-ras codon 12/13)
The 50 ng of genomic DNA were amplified by Ex-taq
polymerase (TaKaRa, Kyoto, Japan) and labeled by PCR
with fluorescent (FITC) labeled primers. PCR was per-
formed under conditions of 94°C:1 min, 55°C:2 min,
72°C:1 min. (35 cycles). The forward and the reverse
primer sequence is GACTGAATATAAACTTGTGG and
CTATTGTTGGATCATATTCG, respectively. Hybridiza-
tion and Image analysis were performed using FD10,
according to the procedure by Maekawa et al [11].
Results
Sample preparation
Both total RNA and genomic DNA were extracted from
each EUS-FNA specimen (See Table S1, Additional file 1)
and pancreatic juice (See Table S2, Additional file 2). In
EUS-FNA specimens, the weight of each specimen was in
the range from 10 to 200 mg. The average amounts of
obtained total RNA were 4.92 ± 3.09 μg (n = 4) (260/
280:1.68 ± 0.26) at frozen storage and 2.51 ± 3.49 μg (n =
13) (260/280:1.70 ± 0.14) at RNAlater® storage, respec-
tively. In each of the frozen samples of pancreatic juices,
pellets were formed in gel-like form. On the other hand,
in each of the RNA later-storage samples of pancreatic
juices, white pellet were formed. The average amounts of
obtained total RNA were 3.94 ± 3.98 μg (n = 6) (260/
280:1.63 ± 0.23) at frozen storage and 0.44 ± 0.66 μg (n =
10) (260/280:1.55 ± 0.31) at RNAlater® storage, respec-
tively. Only small total RNA could be obtained by sam-
ples of RNAlater® storage.
The quality and degradation of total RNA was checked
by electrophoresis. In EUS-FNA specimens, RNA degra-
dations were observed in all the samples of frozen stor-
age. On the other hand, in RNAlater® stored samples, 5 of
13 samples showed both bands of 16 s and 28 s rRNA. In
pancreatic juice samples, almost all sample of frozen stor-
age showed two bands of rRNA, but in RNAlater® stored
samples, almost all samples showed RNA degradations.
After the treatment with DNase, the 0.1-2 μg of total
RNA was amplified using Eberwine's method. The aver-
age of aRNA amplifications in EUS-FNA specimens were
129 ± 99 and 252 ± 253 fold in frozen and RNAlater® stor-
age, respectively. In pancreatic juices samples, 298 ± 142
and 235 ± 149 in frozen and RNAlater® storage, respec-
tively. The RNA sample with good quality confirmed by
electrophoresis showed efficient aRNA amplification
(Table S1, Additional file 1 and Table S2, Additional file
2).
Gene Expression Analysis
We optimized the technique of enzymatic hybridization
signal amplification by applying TSA technology to the
3D structure of our microarray [12]. As a result, fluores-
cent molecules accumulated at the surface of the multiple
pores, and approximately 1000-fold signal amplification
was realized when compared with the conventional
microarray method. Each hybridization was performed
with only 50 ng of aRNA labeled with biotin.
The samples with two-bands of rRNAs in electrophore-
sis and with an efficient rate of aRNA amplification (over
300-fold) were analyzable on the microarray hybridiza-
tion showing sufficient signal intensity on most of the
spots. However, the other samples did not hybridize on
the microarray at all. The analyzable rate with the
microarray was 46% (6/13) in EUS-FNA specimens of
RNAlater® storage. In pancreatic juices, analyzable rate
was 67% (4/6) in frozen storage samples and 20% (2/10) in
RNAlater® storage. After each hybridization, hybridiza-
tion images were automatically taken by the CCD camera
integrated in the FD10, and original image analysis soft-
ware calculated the fluorescence intensity of each spot
and subtracted the background value. Six of those data
from EUS-FNA specimens and six data from the pancre-
atic juice previously obtained were applied to hierarchical
clustering analysis using Spotfire DecisionSite Functional
Genomics http://www.spotfire.com/ with 25 genes,
which showed sufficient signal intensity in most of the
samples.
In the gene expression analysis, the samples were classi-
fied into two clusters, EUS-FNA samples and pancreatic
juice samples (pellets after centrifugation), by the 1st clus-
tering (Figure 3, line A). The cluster of the EUS-FNA
Figure 3 Hierarchical cluster of the human 25 genes expression 
pattern in 12 pancreatic samples. FNA, EUS-FNA specimens (n = 6); 
PJ, pancreatic juice samples (n = 6); PC, pancreatic cancer (n = 5); CP, 
chronic pancreatitis (n = 3); IPMC, intraductal papillary mucinous ade-
nocarcinoma (n = 1); IPMA, intraductal papillary mucinous adenoma (n 
= 2); PET, pancreatic endocrine tumor (n = 1). Each color scale repre-
sents the signal intensity of each gene. Some genes that significantly 
contributed to the dividing of clusters (p < 0.005) were noted at the 
bottom of the panel. Line A shows the boundary of the gene expres-
sion pattern between EUS-FNA and pancreatic juice. Line B shows the 
boundary of cancer or non-cancer in the EUS-FNA specimens.
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sample was further classified into cancerous or non-can-
cerous clusters by the 2nd clustering (Figure 3, line B).
Conversely, the cluster of pancreatic juice samples were
not clearly classified as cancerous and non-cancerous
cluster. The genes, ALP1, MUC1, CCND1, CDK2 and
FHIT significantly contributed to the 1st  clustering
between the EUS-FNA samples and the pancreatic juice
samples (p < 0.05). On the other hand, in the EUS-FNA
samples, the gene, CDK2A, CD44, S100A4 and MUC1
were specifically related to the 2nd clustering between
cancer and non-cancer (p < 0.05).
Gene mutation analysis (K-ras codon 12/13)
PCR amplification and gene mutation analysis for K-ras
(codon12/13) were successful in the case of the samples
with good quality total RNA. We extracted the total RNA
and DNA from the same specimens in this study. When
one nucleic acid could not be successfully prepared and
analyzed, the other nucleic acid also could not be used.
The degradation of the nucleic acid seems to be
depended on the condition of sample storage after EUS-
FNA or collecting pancreatic juices. All of the analyzable
pancreatic cancer samples showed a specific mutation of
K-ras codon12 with a single base change from GGT (Gly)
to GAT (Asp) (See Table S3, Additional file 3), which is
the most frequent mutation, as previously reported [13].
Additionally, one of the analyzable chronic pancreatitis
samples showed a mutation from GGT (Gly) to GTT
(Val), which is also frequent in pancreatic cancer as previ-
ously reported. No mutation could be detected in the
samples of autoimmune pancreatitis and pancreatic
endocrine tumor.
Disscussion
DNA microarrays can analyze plural gene expression
changes at the same time. It is useful for the early detec-
tion of pancreatic cancer, evaluation of malignant poten-
tial and drug efficacy. There are some articles about the
identification of genes that show chemosensitivity to
anti-cancer drugs, such as gemcitabine and 5FU in the
pancreatic cancer cell line [14,15]. Gene expression pro-
filing would especially help to predict the effectiveness of
chemotherapy. This time, we inspected whether gene
expression analysis by 3D microarray was possible using
small amount samples obtained endoscopically.
In EUS-FNA specimens, the sample storage method
using RNAlater® seemed to improve the quality of the
total RNA when compared with the method using liquid
nitrogen storage. Since pancreatic tissues have large
amounts of digestive enzymes, i.e., protease and/or
nuclease, nucleic acids could easily be degraded. Further-
more, since EUS-FNA specimens are long and thin, they
may be easily broken down by digestive enzymes. On the
other hand, a reagent such as an RNase inhibitor included
in RNAlater® may be easy to instill into the tissues and/or
their cell components for the same reason. Therefore,
EUS-FNA specimens may be suitable for storage with
RNAlater® for RNA preparation. In our investigation, the
analyzable rate was lower than 50% for EUS-FNA speci-
mens of RNAlater® storage (46%). For further improve-
ment, it will be very important to take as many cell-rich
EUS-FNA specimens as possible. Actually, specimens
that we couldn't obtain from contained much fibrotic tis-
sue or blood instead of cells (data not shown). After EUS-
FNA, confirmation of the cell component by microscopic
observation and preservation of only cell-rich part with
RNAlater® cutting off from the obtained specimens will be
efficient before RNA preparation.
In pancreatic juice samples, total RNA and DNA were
obtained in good quality and quantity from the directly
frozen samples. RNAlater®  storage could not improve
quality of nucleic acid in pancreatic juice. All those sam-
ples involved white pellet. We suspected that the compo-
nent of white pellet was a contrast agent contained in the
pancreatic juice samples. To confirm it, we mixed RNAl-
ater® and the contrast agent Urografin®, and the white pel-
lets like in RNAlater®-stored samples were observed
immediately. Furthermore, the volume of the white pel-
lets appeared were almost the same as that of Urografin®.
The contrast agent is difficult to be dissolved, therefore,
when it is mixed with different solution such as RNAl-
ater®, its composition changes and the contrast agent may
precipitate. If we use RNAlater® for pancreatic juice stor-
age, we have to remove the supernatant containing a con-
trast agent such as Urografin®, for example, by performing
centrifuge. After then, only the precipitation including
pancreatic cells should be stored with RNAlater®. Further-
more, control experiments with RNase inhibitors other
than RNAlater® to exclude the possible vehicle effects will
be needed. Pancreatic juice is an ideal specimen for pan-
creatic cancer biomarkers discovery, because it is an
exceptionally rich source of proteins released from pan-
creatic cancer cells [16-18]. Gene analysis of pancreatic
juice deserves further investigation to determine its util-
ity as a tool for the evaluation of pancreatic lesions.
It may be presumed that FNA samples and pancreatic
juice samples were classified into different clusters
because the cell population is different in the two kinds of
samples. The gene expression data obtained in this study
succeeded in classifying cancer and non-cancer in the
EUS-FNA samples. However, the pancreatic juice sam-
ples were not classified as any particular cluster. One of
the reasons may be that the pancreatic juice samples were
composed of various kinds of diagnostic samples.
Patient-tailored medicine can be defined as the selec-
tion of specific therapeutics to treat disease in a particu-
lar individual based on genetic, genomic or proteomicNonogaki  et al.  Journal of Experimental & Clinical Cancer Research 2010,
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information. While individualized treatments have been
used in medicine for many years, advances in cancer
treatment have now generated a need to more precisely
define and identify those patients who will derive the
most benefit from new-targeted agents [19,20]. We suc-
c e e d e d  i n  g e n e  e x p r e s s i o n  a n a l y s i s  a n d  g e n e  m u t a t i o n
analysis using the small amount samples by the newly
developed 3D microarray system. The gene expression
analysis and gene mutation analysis requires only 2 days
and 4 hours after the isolation of samples to obtain data.
The 3D microarray has potential for providing detailed
information about the pancreatic lesions from small sam-
ples such as EUS-FNA specimens and pancreatic juices.
It is very difficult to correctly determine the detection
limit of microarray analysis for mRNA expression pattern
and mutation identification. However, from the view-
point of clinical use, we recommend that at least 0.1-2 ug
of total RNA will be sufficient for mRNA expression anal-
ysis. On the other hand, for gene mutation analysis, 50 ng
of genomic DNA were used for conventional PCR in this
study. The detection limit of mutant alleles by the 3D
microarray is estimated to be 16-25% of the total genomic
DNA as previously reported [11].
Conclusions
Gene analysis from small amount samples obtained
endoscopically was possible by newly developed 3D
microarray technology. High quality RNA from EUS-
FNA samples were obtained and remained in good condi-
tion only using RNA stabilizer. In contrast, high quality
RNA from pancreatic juice samples were obtained only in
frozen storage without RNA stabilizer.
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